Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
EQUINE HERPES VIRUS TYPE 1, STRAIN RAC-H INACTIVATED EQUINE HERPES VIRUS TYPE 4, STRAIN 2252 INACTIVATED INFLUENZA VIRUS ANTIGEN STRAIN A/EQUI 1/PRAGUE 56 INACTIVATED INFLUENZA VIRUS ANTIGEN STRAIN A/EQUI 2/NEWMARKET 1/93 INACTIVATED INFLUENZA VIRUS ANTIGEN STRAIN A/EQUI 2/NEWMARKET 2/93 INACTIVATED
Intervet Ireland Limited
QI05AA04
Suspension for Injection
Immunological - Inactivated vaccine
Equine - Food
2001-04-10
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Equilis Resequin Suspension for injection, for horses 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCES: Per dose (2 ml) Inactivated equine herpes virus type 1 (EHV1), strain RAC-H at least 10 7.8 TCID 50 * Inactivated equine herpes virus type 4 (EHV4), strain 2252 at least 10 6.5 TCID 50 * Inactivated equine influenza virus-antigens of the strains A/equi 1/Prague/1/56 50 microgram HA** A/equi 2/Newmarket/1/93 (American type) 20 microgram HA A/equi 2/Newmarket/2/93 (European type) 20 microgram HA ADJUVANTS: Aluminium hydroxide 15 mg Immunostim 1) 40 microlitre 1) Consisting of emulsified cell wall extract of _Myocobacterium phleil._ EXCIPIENT: Sodium timerfonate 50 microgram For a full list of excipients, see section 6.1. * Tissue culture infective dose 50%; Antigen concentration that induces antibody levels in mice of 1:16 for EHV1 and 1:80 for EHV4 ** Haemagglutinin; Antigen concentration that induces antibody levels in guinea pigs not significantly lower than reference preparation 3 PHARMACEUTICAL FORM Suspension for injection 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For active immunisation of horses and ponies for reduction of respiratory disease caused by equine herpesvirus type 1 (EHV 1), equine herpesvirus type 4 (EHV 4) and equine influenza viruses (EIV) of A/equi 1 and the current “American” and “European” strains of A/equi 2. Specific claims EHV 1: In the presence of field infections the vaccine induces complement fixing (CF) and virus neutralising (VN) antibody titres leading to a significant reduction of the duration of virus excretion and a notable reduction of the virus re-isolation rate compared to IRISH MEDICINES BOARD ______ Preberite celoten dokument